FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4285395635> ?p ?o ?g. }

• W4285395635 endingPage "17" @default.
• W4285395635 startingPage "1" @default.
• W4285395635 abstract "Glioblastoma (GBM) is the most common primary malignant brain tumor in adults. Temozolomide (TMZ) is used as the standard chemotherapeutic agent for GBM but with limited success, and treatment failure is mainly due to tumor resistance. One of the leading causes of TMZ resistance is the upregulation of the DNA repair mechanism. Therefore, targeting the DNA damage response (DDR) is proposed to be an effective strategy to sensitize tumor cells to TMZ. In the present study, we demonstrated that the combined use of the PI3K inhibitor ZSTK474 and TMZ showed synergetic anticancer effects on human GBM cells in vitro and in vivo. The combination treatment led to significantly increased cell apoptosis and DNA double strand breaks (DSBs). In addition, a mechanistic study indicated that TMZ enhanced the homologous recombination (HR) repair efficiency in GBM cells, while ZSTK474 impaired HR repair by blocking the phosphorylation of ATM and the expression of BRCA1/2 and Rad51, thereby sensitizing GBM cells to TMZ. Moreover, TMZ activated the PI3K signaling pathway through upregulation of the PI3K catalytic subunits p110α and p110β and the phosphorylation of Akt. Meanwhile, ZSTK474 blocked the activity of the PI3K/Akt pathway. Taken together, our findings suggested that the combination of ZSTK474 and TMZ might be a potential therapeutic option for GBM." @default.
• W4285395635 created "2022-07-14" @default.
• W4285395635 creator A5015063511 @default.
• W4285395635 creator A5015899762 @default.
• W4285395635 creator A5037706563 @default.
• W4285395635 creator A5041351667 @default.
• W4285395635 creator A5049290197 @default.
• W4285395635 creator A5049332313 @default.
• W4285395635 creator A5051668284 @default.
• W4285395635 creator A5057730667 @default.
• W4285395635 creator A5069478232 @default.
• W4285395635 date "2022-07-13" @default.
• W4285395635 modified "2023-09-27" @default.
• W4285395635 title "ZSTK474 Sensitizes Glioblastoma to Temozolomide by Blocking Homologous Recombination Repair" @default.
• W4285395635 cites W1677659983 @default.
• W4285395635 cites W1926957395 @default.
• W4285395635 cites W1969043065 @default.
• W4285395635 cites W1969762630 @default.
• W4285395635 cites W1984919526 @default.
• W4285395635 cites W2009886463 @default.
• W4285395635 cites W2020825769 @default.
• W4285395635 cites W2037882207 @default.
• W4285395635 cites W2064720809 @default.
• W4285395635 cites W2073067473 @default.
• W4285395635 cites W2077945404 @default.
• W4285395635 cites W2089482729 @default.
• W4285395635 cites W2092000556 @default.
• W4285395635 cites W2102348612 @default.
• W4285395635 cites W2117988802 @default.
• W4285395635 cites W2120806256 @default.
• W4285395635 cites W2121205576 @default.
• W4285395635 cites W2130084494 @default.
• W4285395635 cites W2134807618 @default.
• W4285395635 cites W2155318349 @default.
• W4285395635 cites W2164995160 @default.
• W4285395635 cites W2165404212 @default.
• W4285395635 cites W2320193046 @default.
• W4285395635 cites W2412343702 @default.
• W4285395635 cites W2474366905 @default.
• W4285395635 cites W2504774957 @default.
• W4285395635 cites W2509099384 @default.
• W4285395635 cites W2526011086 @default.
• W4285395635 cites W2561471811 @default.
• W4285395635 cites W2584466409 @default.
• W4285395635 cites W2614302791 @default.
• W4285395635 cites W2621838563 @default.
• W4285395635 cites W2625452721 @default.
• W4285395635 cites W2800469107 @default.
• W4285395635 cites W2890744696 @default.
• W4285395635 cites W2921818265 @default.
• W4285395635 cites W2921991537 @default.
• W4285395635 cites W2982198933 @default.
• W4285395635 cites W2990276604 @default.
• W4285395635 cites W3007055263 @default.
• W4285395635 cites W3009192043 @default.
• W4285395635 cites W3013766872 @default.
• W4285395635 cites W3015444296 @default.
• W4285395635 cites W3040909718 @default.
• W4285395635 cites W3109004754 @default.
• W4285395635 cites W3110156846 @default.
• W4285395635 cites W3181467631 @default.
• W4285395635 cites W3184638590 @default.
• W4285395635 cites W3187637740 @default.
• W4285395635 cites W3206089510 @default.
• W4285395635 cites W4221014531 @default.
• W4285395635 doi "https://doi.org/10.1155/2022/8568528" @default.
• W4285395635 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35872860" @default.
• W4285395635 hasPublicationYear "2022" @default.
• W4285395635 type Work @default.
• W4285395635 citedByCount "2" @default.
• W4285395635 countsByYear W42853956352023 @default.
• W4285395635 crossrefType "journal-article" @default.
• W4285395635 hasAuthorship W4285395635A5015063511 @default.
• W4285395635 hasAuthorship W4285395635A5015899762 @default.
• W4285395635 hasAuthorship W4285395635A5037706563 @default.
• W4285395635 hasAuthorship W4285395635A5041351667 @default.
• W4285395635 hasAuthorship W4285395635A5049290197 @default.
• W4285395635 hasAuthorship W4285395635A5049332313 @default.
• W4285395635 hasAuthorship W4285395635A5051668284 @default.
• W4285395635 hasAuthorship W4285395635A5057730667 @default.
• W4285395635 hasAuthorship W4285395635A5069478232 @default.
• W4285395635 hasBestOaLocation W42853956351 @default.
• W4285395635 hasConcept C102744134 @default.
• W4285395635 hasConcept C104317684 @default.
• W4285395635 hasConcept C11960822 @default.
• W4285395635 hasConcept C127561419 @default.
• W4285395635 hasConcept C134935766 @default.
• W4285395635 hasConcept C143425029 @default.
• W4285395635 hasConcept C185592680 @default.
• W4285395635 hasConcept C190283241 @default.
• W4285395635 hasConcept C2777389519 @default.
• W4285395635 hasConcept C2778227246 @default.
• W4285395635 hasConcept C2779012473 @default.
• W4285395635 hasConcept C502942594 @default.
• W4285395635 hasConcept C552990157 @default.
• W4285395635 hasConcept C55493867 @default.
• W4285395635 hasConcept C71924100 @default.
• W4285395635 hasConcept C75217442 @default.

• next